Key result
Azilsartan medoxomil causes no clinically meaningful change in drug exposure in mild to moderate hepatic impairment.
Answers are grounded in this paper and cite their sources.
Azilsartan medoxomil (AZL-M) is a potent angiotensin II receptor blocker that decreases blood pressure in a dose-dependent manner. It is a prodrug that is not detected in blood after its oral administration because of its rapid hydrolysis to the active moiety, azilsartan (AZL). AZL undergoes further metabolism to the major metabolite, M-II, and minor metabolites. The objective of this study was to determine the effect of mild to moderate hepatic impairment on the pharmacokinetics of AZL and its major metabolite. This was a single-center, open-label, phase 1 parallel-group study that examined the single-dose (day 1) and multiple-dose (days 4-8) - 40 mg - pharmacokinetics of AZL and M-II in 16 subjects with mild and moderate hepatic impairment by Child-Pugh classification (n = 8 per group) and subjects (n = 16) matched based on age, sex, race, weight, and smoking status. Mild or moderate hepatic impairment did not cause clinically meaningful increases in exposure to AZL and M-II. Mild or moderate hepatic impairment had no clinically meaningful effect on the plasma protein binding of AZL and M-II. Single and multiple doses of AZL-M 40 mg were well tolerated in all subject groups. Based on the pharmacokinetic and tolerability findings, no dose adjustment of AZL-M is required for subjects with mild and moderate hepatic impairment.
No takes yet. Share an insight, caveat, or question.
Dudkowski et al. (2017) studied Mild to moderate hepatic impairment (n=32). Azilsartan medoxomil vs. Matched subjects without hepatic impairment was evaluated on Pharmacokinetics (exposure and plasma protein binding) and tolerability of azilsartan and its major metabolite M-II. Azilsartan medoxomil in mild or moderate hepatic impairment caused no clinically meaningful increases in drug exposure or changes in protein binding.
Synapse has enriched 10 related papers. Consider them for comparative context: